Objective Patients treated in a protective isolation unit (PIU) 
Introduction

Infection is the leading cause of mortality in patients with leukemia and lymphoma and the complications resulting from infection present a profound limitation to aggressive chemotherapy and stem cell transplantation (SCT). One major approach to protecting patients with altered immune defenses from infection is to decrease their exposure to potential pathogens by reducing the concentration of microorganisms in the external environment. The methods used to achieve this end may involve the use of facilities that isolate the patient and filter the room air (1). Patients treated in a protective isolation unit (PIU), however, often experience loneliness and increased feelings of seclusion, which leads to elevated levels of distress. Nearly half of SCT patients treated in isolation exhibit anxiety and fatigue during treatment (2). On the other hand, oncology patients also have a high prevalence of anxiety or depression during hospitalization. Depression and/or anxiety may have a variety of deleterious effects: impaired quality of life (QOL); increased symptom burden and pain intensity; decreased compliance with medical treatment; and increased health care costs and hospital stay (3). Furthermore, there is a well-documented bidirectional association between insomnia and depression: insomnia is an important and frequent symptom of psychologic distress, but also a precursor of depression
. Therefore 
Study design
We referred to the Athens Insomnia Scale (5) 
Results
Patient baseline characteristics
Baseline patient characteristics are shown in Table 1 T r a n s f u s i o n t h e r a p y ( 1 4 c a se s ) , s u p p l e me n t a t i o n wi t h v i t a mi n B 1 2 ( 2 c a s e s ) , a n d r a d i a t i o n t h e r a p y ( 2 c a s e s ) . 
T a b l e 1 . B a s e l i n e P a t i e n t Ch a r a c t e r i s t i c s
P e r c e n t a g e s ma y n o t a d d u p t o 1 0 0 % d u e t o r o u n d i n g -o f f o f f i g u r e s . Ab b r e v i a t i o n s : P I U: p r o t e c t i v e i s o l a t i o n u n i t , S W: s t a n d a r d wa r d , AA: a p l a s t i c a n e mi a , AL L : a c u t e l y mp h o b l a s t i c l e u k e mi a , AML : a c u t e my e l o b l a s t i c l e u k e mi a , MDS : my e l o d y s p l a st i c s y n d r o me , ML : ma l i g n a n t l y mp h o ma , MM: mu l t i p l e my e l o ma , S C T : s t e m-c e l l t r a n s p l a n t a t i o n , C T : c h e mo t h e r a p y , I S : i mmu n o s u p p r e s s i v e t h e r a p y . a I d i o p a t h i c t h r o mb o c y t o p e n i c p u r p u r a ( 8 c a s e s ) , a u t o i mmu n e h e mo l y t i c a n e mi a (
Assessment of insomnia
Assessment of depression
Of 264 patients in our study, 8 (3.0%) patients suffered from depression. Of the 8 patients with depression, 7 patients were under 60 years old, 6 patients received SCT, 7 patients stayed in the hospital for over 75 days, 4 patients received CS therapy, 7 patients had therapeutic complications, and 6 patients were in the PIU (Table 3). A greater percentage of patients in the PIU (6 of 62 patients, 9.7%) than patients in the SW (2 of 184 patients, 1.1%) suffered from depression, but the difference was not statistically different in analysis using a multivariate model. The median interval before presenting with depression after a stay in the PIU (55 days, range 15-71 days) was significantly different from that after a stay in the SW (98 days, range 82-114; p= 0.045). Depression was significantly associated with complications (p=0.042). Length of hospital stay tended to be associated with complications (p=0.059) in the multivariate analysis. All PIU patients who experienced depression after CS therapy had received SCT. Of the 30 PIU patients with complications, 6 (20%) suffered from depression, which was significantly higher than the number of SW patients with
T a b l e 2 . As s e s s me n t o f I n s o mn i a
Un i v a r i a t e p r e d i c t o r s we r e o b t a i n e d b y s i mp l e l o g i s t i c r e g r e s s i
o n a n a l y s i s . Va r i a b l e s h a v i n g a p -v a l u e < 0 . 1 0 i n u n i v a r i a t e l o g i s t i c r e g r e s s i o n a n a l y s i s we r e e n t e r e d a s c a n d i d a t e r i s k f a c t o r s i n mu l t i v a r i a t e l o g i s t i c r e g r e s s i o n mo d e l s . * Va l u e s a r e e x p r e s s e d a s Nu mb e r s . Ab b r e v i a t i o n s : S C T : s t e m-c e l l t r a n s p l a n t a
t i o n , C S : C o r t i c o s t e r o i d , P I U: p r o t e c t i v e i s o l a t i o n u n i t complications (1 of 29, 3.4%). All PIU patients with depression and therapeutic complications had received SCT. Furthermore, all CS-treated patients with depression had stayed in the PIU. Although an episode of depression in the PIU patients might be associated with receiving SCT, use of CS, or therapeutic complications, we could not statistically analyze these composite factors due to the small number of patients.
Discussion
In the present study, the incidence of insomnia and depression was slightly higher in patients in the PIU than in those in the SW, but the difference was not significantly different. Notably, all the PIU patients with depression had received SCT. SCT is a highly aggressive and demanding medical therapy with a profound impact at both the physical and psychologic levels. There have been many studies of the psychologic effects of SCT (2, 3, 7, 8) . The incidence of depression in SCT patients is reported to be 12% to 23% (2, 3, 8) , which is similar to the present result (6 of 50 patients, 12.0%). After SCT, GVHD can have a negative impact on an individual's general and mental health, and can lead to the development of functional impairment and activity limitations (7) . Furthermore, younger age and higher regimen-related toxicity are associated with the risk of developing a psychiatric disorder (3) , and high psychiatric morbidity and a longer hospital length of stay in relation to these factors have also been reported (8) . In the present study, patients in the PIU were younger, had a longer hospital stay, and had more complications, because many of them were hospitalized for SCT. These characteristics of patients in the PIU might be risk factors for developing psychiatric disorders. We assume that the median interval between depression and a stay in the PIU was shorter than that between depression and a stay in the SW because the PIU is a more intensive intervention and the characteristics that require a stay in the PIU might include more risk factors for depression. Based on this study, however, it is not possible to determine whether depression after SCT is related to the protective environment, because the study was retrospective and involved only a small number of patients. Ideally, a prospec-T a b l e 3 . As s e s s me n t o f De p r e s s i o Un i v a r i a t e p r e d i c t o r s we r e o b t a i n e d b y s i mp l e l o g i s t i c r e g r e s s i o n a n a l y s i s . Va r i a b l e s h a v i n g a p -v a l u e < 0 . 1 0 i n u n i v a r i a t e l o g i s t i c r e g r e s s i o n a n a l y s i s we r e e n t e r e d a s c a n d i d a t e r i s k f a c t o r s i n mu l t i v a r i a t e l o g i s t i c r e g r e s s i o n mo d e l s . * Va l u e s a r e e x p r e s s e d a s Nu mb e r s . Ab b r e v i a t i o n s : S C T : s t e m-c e l l t r a n sp l a n t a t i o n , C S : C o r t i c o s t e r o i d , P I U: p r o t e c t i v e i s o l a t i o n u n i t 
